Lessons from the withdrawal of rofecoxib: Patients would be safer if drug companies disclosed adverse events before licensing
AUTOR(ES)
Dieppe, Paul A
FONTE
BMJ Publishing Group Ltd.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=523096Documentos Relacionados
- Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten
- Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs
- What would be conserved if "the tape were played twice"?
- Preventable adverse drug events in critically ill HIV patients: Is the detection of potential drug-drug interactions a useful tool?
- The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada